{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:18:32Z","timestamp":1792685912041,"version":"4.5.0"},"reference-count":40,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal strategy after discontinuation of B-cell depleting therapies like ocrelizumab in people with multiple sclerosis (pwMS) remains uncertain, particularly regarding delayed disease reactivation, disability progression and required treatment duration before cessation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective two-centre observational cohort study with propensity score-matched (PSM) analysis, we evaluated recurrence of disease activity and disability worsening after ocrelizumab discontinuation. PwMS fulfilling the 2017 McDonald criteria were enrolled between January 2018 and December 2023 at two German MS centres. Participants received ocrelizumab for \u226512 months with no inflammatory activity in the preceding 12 months. Of 655 eligible patients (continuers, n=578; discontinuers, n=77), 290 were included after 4:1 PSM. The primary exposure was discontinuation, mainly due to infection concerns during COVID-19 (81%) or hypogammaglobulinaemia (16%). Main outcomes were time to combined inflammatory activity (CIA) and progression independent of relapse activity (PIRA). Receiver operating characteristic (ROC) identified optimal treatment duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After median follow-up of 28.5 months, there was no significant difference in CIA risk between groups (HR: 0.91, 95% CI 0.08 to 10.79) or for PIRA (HR: 4.8, 95%\u2009CI 0.38 to 60.2). Beyond 24 months after discontinuation, disease activity remained stable, with a numerical rise that did not reach statistical significance. ROC analysis suggested no further reduction of activity beyond 29\u201330 months of therapy, but increasing reactivation risk after &gt;32 months off-treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For stable pwMS, ocrelizumab discontinuation after about 30 months on-treatment appears safe short-term, though vigilant monitoring is warranted beyond 2 years off-treatment due to potential delayed reactivation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2025-337944","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:20:20Z","timestamp":1768933220000},"page":"513-521","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity"],"prefix":"10.1136","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-5674","authenticated-orcid":false,"given":"Franz Felix","family":"Konen","sequence":"first","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Axhausen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Justus-Liebig-University Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Neurology, Justus-Liebig-University Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"M\u00fchlenbrock","sequence":"additional","affiliation":[{"name":"Department of Neurology, Justus-Liebig-University Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5695","authenticated-orcid":false,"given":"Stefan","family":"Gingele","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2953-0166","authenticated-orcid":false,"given":"Konstantin Fritz","family":"Jendretzky","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Nay","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea Martha","family":"Grote-Levi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schwenkenbecher","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G","family":"Meuth","sequence":"additional","affiliation":[{"name":"Department of Neurology, Heinrich-Heine-University Dusseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8550-335X","authenticated-orcid":false,"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Pfeuffer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Justus-Liebig-University Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"2026051402050528000_97.6.513.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1401483"},{"key":"2026051402050528000_97.6.513.2","doi-asserted-by":"crossref","first-page":"103312","DOI":"10.1016\/j.autrev.2023.103312","article-title":"Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders","volume":"22","author":"Konen","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2026051402050528000_97.6.513.3","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27034"},{"key":"2026051402050528000_97.6.513.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"2026051402050528000_97.6.513.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"2026051402050528000_97.6.513.6","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01104-8"},{"key":"2026051402050528000_97.6.513.7","doi-asserted-by":"crossref","unstructured":"Nobile S , Beauchemin P . Hypogammaglobulinemia and Infection Risk in an Ocrelizumab-treated Multiple Sclerosis Cohort. Can J Neurol Sci 2024;1\u20138. doi:10.1017\/cjn.2024.21","DOI":"10.1017\/cjn.2024.21"},{"key":"2026051402050528000_97.6.513.8","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-025-13133-w","article-title":"Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis","volume":"272","author":"Davies","year":"2025","journal-title":"J Neurol"},{"key":"2026051402050528000_97.6.513.9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1177\/13524585211055593","article-title":"Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-\"Yes\"","volume":"28","author":"Rolfes","year":"2022","journal-title":"Mult Scler"},{"key":"2026051402050528000_97.6.513.10","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00154-0"},{"key":"2026051402050528000_97.6.513.11","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026051402050528000_97.6.513.12","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamaneurol.2024.0395","article-title":"High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS","volume":"81","author":"Jouvenot","year":"2024","journal-title":"JAMA Neurol"},{"key":"2026051402050528000_97.6.513.13","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.1007\/s00415-024-12584-x","article-title":"MS treatment de-escalation: review and commentary","volume":"271","author":"Selmaj","year":"2024","journal-title":"J Neurol"},{"key":"2026051402050528000_97.6.513.14","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40263-023-01038-z","article-title":"Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies","volume":"37","author":"Prosperini","year":"2023","journal-title":"CNS Drugs"},{"key":"2026051402050528000_97.6.513.15","first-page":"e1926","article-title":"Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis","volume":"99","author":"Roos","year":"2022","journal-title":"Neurology (ECronicon)"},{"key":"2026051402050528000_97.6.513.16","doi-asserted-by":"crossref","first-page":"105900","DOI":"10.1016\/j.msard.2024.105900","article-title":"The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis","volume":"91","author":"Coerver","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"2026051402050528000_97.6.513.17","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13311-022-01289-6","article-title":"Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic","volume":"19","author":"Zangh\u00ec","year":"2022","journal-title":"Neurotherapeutics"},{"key":"2026051402050528000_97.6.513.18","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211028833"},{"key":"2026051402050528000_97.6.513.19","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"2026051402050528000_97.6.513.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"2026051402050528000_97.6.513.21","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-335673"},{"key":"2026051402050528000_97.6.513.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00095-8"},{"key":"2026051402050528000_97.6.513.23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"2026051402050528000_97.6.513.24","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww173"},{"key":"2026051402050528000_97.6.513.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2005.00356.x"},{"key":"2026051402050528000_97.6.513.26","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad358","article-title":"Risk of T2 lesions when discontinuing fingolimod: a nationwide predictive and comparative study","volume":"6","author":"Wandall-Holm","year":"2024","journal-title":"Brain Commun"},{"key":"2026051402050528000_97.6.513.27","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200110","article-title":"Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy","volume":"10","author":"Hellwig","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026051402050528000_97.6.513.28","doi-asserted-by":"crossref","first-page":"122781","DOI":"10.1016\/j.jns.2023.122781","article-title":"Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State Multiple Sclerosis Consortium (NYSMSC) study","volume":"455","author":"Jakimovski","year":"2023","journal-title":"J Neurol Sci"},{"key":"2026051402050528000_97.6.513.29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44750","article-title":"Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy","volume":"5","author":"Hellwig","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026051402050528000_97.6.513.30","first-page":"e723","article-title":"Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis","volume":"92","author":"Honce","year":"2019","journal-title":"Neurology (ECronicon)"},{"key":"2026051402050528000_97.6.513.31","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/13524585251329849","article-title":"Suboptimal B-cell depletion is associated with progression independent of relapse activity in multiple sclerosis patients treated with ocrelizumab","volume":"31","author":"Revie","year":"2025","journal-title":"Mult Scler"},{"key":"2026051402050528000_97.6.513.32","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00328-4"},{"key":"2026051402050528000_97.6.513.33","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"key":"2026051402050528000_97.6.513.34","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112383","article-title":"Comprehensive analysis of B cell repopulation in ocrelizumab-treated patients with multiple sclerosis by mass cytometry and proteomics","volume":"28","author":"Wang","year":"2025","journal-title":"iScience"},{"key":"2026051402050528000_97.6.513.35","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol"},{"key":"2026051402050528000_97.6.513.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.01.025"},{"key":"2026051402050528000_97.6.513.37","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241277736","article-title":"Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials","volume":"17","author":"Derfuss","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"2026051402050528000_97.6.513.38","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200167","article-title":"Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity","volume":"10","author":"Bose","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026051402050528000_97.6.513.39","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jamaneurol.2024.1961","article-title":"Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis","volume":"81","author":"Gavoille","year":"2024","journal-title":"JAMA Neurol"},{"key":"2026051402050528000_97.6.513.40","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ana.27143","article-title":"Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab","volume":"97","author":"Meuth","year":"2025","journal-title":"Ann Neurol"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2025-337944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:06:23Z","timestamp":1778749583000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2025-337944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,5,14]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/jnnp-2025-337944"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2025-337944","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}